The note reveals that Goldman has initiated coverage with a buy rating and $48.90 price target on ResMed's shares. Based on ...

Goldman Sachs initiated coverage on ResMed Inc (NYSE:RMD) with a "Buy" rating and a price target of A$48.9, driven by strong growth prospects in its continuous airway pressure (CPAP) therapy segment.

Bell Potter has a buy rating and $34.00 price target on its shares. This suggests that upside of 20% is possible from current levels. Goldman Sachs has just initiated coverage on ResMed and named it ...

Dave Whelan's requests for a sleep apnoea test were repeatedly ignored until he suffered a near fatal crash on the M11 which ...

Here's why brokers are feeling bullish about these three shares this week. The post Brokers name 3 ASX shares to buy today ...

Goldman Sachs initiated coverage of ResMed (RMD) with a Buy rating and A$48.90 price target The firm says its Buy thesis is based on “robust” ...

Investing.com -- Goldman Sachs initiated coverage on ResMed Inc (NYSE ... strong growth prospects in its continuous airway pressure (CPAP) therapy segment.

The latest edition of STAT’s Health Tech newsletter brings you important dispatches from the J.P. Morgan Health Care ...

CR shares expert guidance on the best sleep position, pillows, mattresses, and more if you have sleep apnea, GERD, asthma, ...

The Dallas Cowboys' search for the franchise's next head coach is underway. On Monday, longtime Cowboys owner and general manager Jerry Jones confirmed that the organization and coach Mike ...

2-Year U.S. Treasury Note Continuous Contract $102.707-0.098-0.09% 5-Year U.S. Treasury Note Continuous Contract $106.078-0.188-0.18% 10-Year U.S. Treasury Note Continuous Contract $108.406-0.203 ...

Sleep and respiratory disorders sector of the medical device industry ("Sleep and Respiratory Care') and the supply of business management software as a service to out-of-hospital health providers ...